LOXL3 and melanoma: Analysis of the influence of LOXL3, NES, and SNAI1 expression data from the TCGA melanoma database on the survival rates in patients discovered that in the group of BRAF+ melanoma patients, there was no significant difference in survival times between the high- and low-expression groups of LOXL3 and SNAI1.